Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa

项目 2：马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素

• 批准号: 10652401
• 负责人: Dirk P Dittmer
• 金额: $ 18.45万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-13 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10652401
• 关键词: AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; AIDS with Kaposi' s sarcoma; Adopted; Africa; Africa South of the Sahara; Area; Biological; Biopsy; Bleomycin; Blood; Caring; Cells; Clinical; Clinical Markers; Clinical Trials; Cohort Studies; Collaborations; Collection; Country; Data Set; Detection; Disease; Disease Marker; Eligibility Determination; Enrollment; Europe; Funding; Gene Expression Profile; Gene Expression Profiling; Genetic Transcription; Genome; Genomics; Goals; HIV; Hospitals; Human; Human Herpesvirus 8; IL6 gene; Incidence; Institutional Review Boards; Interleukin-10; Iris; Joints; Kaposi Sarcoma; Link; Liposomal Doxorubicin; Lymphoma; Lymphoproliferative Disorders; Malawi; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of prostate; Mentors; Molecular; North Carolina; Nucleotides; Paclitaxel; Pathogenesis; Pathology; Patients; Persons; Population; Positioning Attribute; Productivity; Prognosis; Prognostic Factor; Prognostic Marker; Public Sector; Publications; Research; Research Personnel; Saliva; Shipping; Site; South Africa; Stains; Testing; Time; Trust; United States National Institutes of Health; Universities; Variant; Vincristine; Viral; Viral Load result; Work; base; biomarker performance; cohort; exceptional responders; exosome; experience; genome sequencing; innovation; low and middle-income countries; men; molecular marker; outcome prediction; randomized, clinical trials; response; response biomarker; screening; sex; standard of care; treatment guidelines; treatment response; whole genome

ABSTRACT: PROJECT 2. Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa This application seeks to establish the UNC-Malawi-South Africa Cancer Consortium (UMSACC). It responds to RFA-CA-20-001 and will establish a research center to develop capacity and conduct high-impact research focused on HIV-Associated Malignancy in U.S. and Low- and Middle-Income Country. Project 2 - Kaposi Sarcoma builds on longstanding collaborations between the University of North Carolina at Chapel Hill, Lighthouse Trust / Kamuzu Central Hospital in Malawi, and Stellenbosch University / Tygerberg Hospital in South Africa. This project has participation of investigators from all three countries: the US, Malawi and South Africa. UMSACC will establish and maintain core that support mentoring, administration, pathology and analyses jointly across three projects. Kaposi sarcoma is by far the most common cancer in people living in with HIV in Sub Saharan Africa and the US standard of care, liposomal doxorubicin, is not affordable or available in the public sector. Building on recent randomized clinical trials by the AIDS malignancy Consortium and the AIDS clinical trials group, we will document the experience with paclitaxel/ cART as new first line therapy in HIV-KS and seek to develop prognostic biomarkers of the disease, such as KSHV viral load, IL6, KSHV sequence variants and KSHV transcription.

摘要：项目 2. HIV 相关卡波西肉瘤的临床和分子决定因素 马拉维和南非当地标准护理治疗下的进展 该申请旨在建立北卡罗来纳大学-马拉维-南非癌症联盟 (UMSACC)。它响应 RFA-CA-20-001，并将建立一个研究中心来发展能力并进行高影响力的研究 专注于 美国和中低收入国家的艾滋病毒相关恶性肿瘤。项目2-卡波西 肉瘤建立在北卡罗来纳大学教堂山分校之间的长期合作基础上， 马拉维灯塔信托基金/卡穆祖中央医院和斯泰伦博斯大学/泰格伯格医院 南非。该项目有来自三个国家的调查人员参与：美国、马拉维和南苏丹 非洲。 UMSACC 将建立和维护支持指导、管理、病理学和 联合分析三个项目。卡波西肉瘤是迄今为止生活在人们中最常见的癌症 撒哈拉以南非洲地区的艾滋病毒感染者和美国的护理标准脂质体阿霉素是负担不起的，或者 在公共部门可用。以艾滋病恶性肿瘤联盟最近的随机临床试验为基础 和艾滋病临床试验小组，我们将记录紫杉醇/ cART 作为新一线药物的经验 HIV-KS 治疗并寻求开发该疾病的预后生物标志物，例如 KSHV 病毒载量、IL6、 KSHV 序列变体和 KSHV 转录。